BetterLife's Non-hallucinogenic LSD For Treating Mood Disorders Highlighted in Drug Discovery & Development Article Pharmaceutical Investing
Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human Trials Pharmaceutical Investing
Silo Wellness Eliminates Another CAD$4,440,000 of Debt from Balance Sheet by Disposing of Subsidiary Psychedelics Investing
Goodness Growth Holdings to Report Fourth Quarter and Full Year 2022 Results on March 30, 2023 Psychedelics Investing
Lobe Sciences Ltd. Announces That The Drug Enforcement Administration Has Issued The Initial 2023 Quota Allowing Export Of L-130 Pharmaceutical Investing
Promise of BetterLife's Non-hallucinogenic LSD For Treating Mood Disorders Highlighted in Medical Xpress Article Pharmaceutical Investing
BetterLife Files Amended and Restated Offering Document for Offering of Units Pharmaceutical Investing
Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock Psychedelics Investing
Omineca Announces Upsized and Fully Allocated $2.8 Million Brokered Financing of Flow-Through Units Pharmaceutical Investing
Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors
